A biomimetic oxygen-generating nanoplatform for enhanced sonodynamic immune activation.

Authors

Haiqin Liao, Shiyu Ding, Ming Zhang, Quanliang Shang, Zhigang Wang

Published in

Journal of applied biomaterials & functional materials. Volume 24. Pages 22808000261464863. Epub Jul 04, 2026.

Abstract

BackgroundSonodynamic therapy (SDT) has emerged as a promising strategy for cancer treatment; however, its therapeutic efficacy is significantly limited by the hypoxic tumor microenvironment, particularly in breast cancer. To address this limitation, we developed a biomimetic nanoplatform capable of generating oxygen within the tumor microenvironment to enhance SDT performance.MethodsPoly (lactic-co-glycolic acid) (PLGA) nanoparticles were co-loaded with catalase and the sonosensitizer IR780 and subsequently coated with 4T1 cancer cell membranes (CIP@4T1m NPs). A series of in vitro and in vivo experiments were conducted to evaluate tumor-targeting capability, hypoxia alleviation, singlet oxygen (¹O₂) generation, antitumor efficacy, induction of immunogenic cell death (ICD), and activation of antitumor immune responses.ResultsThe resulting CIP@4T1m NPs were successfully fabricated and exhibited preferential accumulation in 4T1 tumor cells and orthotopic 4T1 tumor-bearing mice. Both in vitro and in vivo studies demonstrated that the nanoplatform partially relieved tumor hypoxia and significantly enhanced SDT-mediated ¹O₂ production and antitumor effects. Moreover, CIP@4T1m NPs combined with ultrasound induced ICD-associated changes, promoted dendritic cell maturation, facilitated the polarization of tumor-associated macrophages from the M2 to M1 phenotype, reduced regulatory T cell populations, and increased intratumoral CD8⁺T-cell infiltration.ConclusionThis work describes a biomimetic nanoplatform that integrates homologous targeting with enzymatic oxygen generation to enhance SDT efficacy and promote antitumor immune responses in an orthotopic 4T1 breast cancer model. The proposed strategy offers a potential approach to mitigate hypoxia-associated limitations in cancer therapy.

PMID:
42400360
Bibliographic data and abstract were imported from PubMed on 04 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.